These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3931953)

  • 1. Premarketing observational studies of population pharmacokinetics of new drugs.
    Sheiner LB; Benet LZ
    Clin Pharmacol Ther; 1985 Nov; 38(5):481-7. PubMed ID: 3931953
    [No Abstract]   [Full Text] [Related]  

  • 2. Relevance of genetic polymorphism in drug metabolism in the development of new drugs.
    Balant LP; Gundert-Remy U; Boobis AR; von Bahr C
    Eur J Clin Pharmacol; 1989; 36(6):551-4. PubMed ID: 2673794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research in the field of clinical pharmacology in the USSR].
    Lakin KM; Makarov VA; Novikova NV
    Farmakol Toksikol; 1982; 45(3):5-12. PubMed ID: 7047211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug assays in the assessment of the clinical value and safety of new compounds.
    Campbell DB
    Contemp Issues Clin Biochem; 1985; 3():33-60. PubMed ID: 3915972
    [No Abstract]   [Full Text] [Related]  

  • 5. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.
    Zhang R; Monsma F
    Expert Opin Drug Discov; 2010 Nov; 5(11):1023-9. PubMed ID: 22827742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new era in the study of individual differences in drug metabolism and pharmacokinetics.
    Yokoi T
    Drug Metab Pharmacokinet; 2013; 28(1):1-2. PubMed ID: 23438895
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug metabolism and drug kinetics as basis for clinical testing of new drugs].
    Bickel MH
    Ther Umsch; 1971 Apr; 28(4):250-6. PubMed ID: 4930185
    [No Abstract]   [Full Text] [Related]  

  • 8. The significance of properly designed pre-clinical studies in the clinical evaluation of new drugs.
    Garrett ER
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):6-20. PubMed ID: 4924331
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical trials of drugs without immediate therapeutic objectives].
    Cheymol G
    Ann Med Interne (Paris); 1987; 138(3):173-7. PubMed ID: 3619247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors contributing to variability in drug pharmacokinetics. III. Metabolism.
    Jack DB
    J Clin Hosp Pharm; 1985 Mar; 10(1):25-43. PubMed ID: 3889063
    [No Abstract]   [Full Text] [Related]  

  • 11. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability.
    Kalow W; Endrenyi L; Tang B
    Pharmacology; 1999 Jun; 58(6):281-4. PubMed ID: 10325572
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacokinetics and clinical testing of drugs. (Notes on a study trip in the USA)].
    Mikulecký M
    Bratisl Lek Listy; 1978 May; 69(5):597-611. PubMed ID: 656972
    [No Abstract]   [Full Text] [Related]  

  • 13. New techniques in drug metabolism and clinical pharmacology/pharmacokinetics.
    Benet LZ
    Am Biotechnol Lab; 1993 Feb; 11(2):44-7. PubMed ID: 7763426
    [No Abstract]   [Full Text] [Related]  

  • 14. Basic principles of pharmacokinetics.
    Nightingale CH; Carver P
    Clin Lab Med; 1987 Jun; 7(2):267-78. PubMed ID: 3301169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies.
    Yasuda SU; Zhang L; Huang SM
    Clin Pharmacol Ther; 2008 Sep; 84(3):417-23. PubMed ID: 18615002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations of pharmacokinetics of drugs in patients with cirrhosis.
    Pena MA; Horga JF; Zapater P
    Expert Rev Clin Pharmacol; 2016; 9(3):441-58. PubMed ID: 26696448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical pharmacokinetics as part of clinical pharmacology.
    Gladtke E
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):37-41. PubMed ID: 4924326
    [No Abstract]   [Full Text] [Related]  

  • 18. Chirality in new drug development. Clinical pharmacokinetic considerations.
    Nation RL
    Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of metabolism and disposition studies in the safety assessment of pharmaceuticals.
    Smith RL
    Xenobiotica; 1988 Jan; 18 Suppl 1():89-96. PubMed ID: 3278491
    [No Abstract]   [Full Text] [Related]  

  • 20. [Drug interactions: methological problems].
    Patat A
    Therapie; 1995; 50(3):203-14. PubMed ID: 7667800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.